Using a monoclonal antibody to protect the heart after a heart attack
Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failure
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10904984
This study is looking at how a special treatment can help your heart heal better after a heart attack by blocking a specific enzyme that makes recovery harder, with the hope of preventing heart failure for people like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10904984 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting a specific enzyme in the heart with a monoclonal antibody can help prevent heart failure following a heart attack. The study focuses on the role of ectonucleotidase ENPP1, which is known to increase after a heart attack and contribute to inflammation and poor healing. By inhibiting this enzyme, the research aims to improve cardiac repair and reduce the risk of heart failure in patients who have suffered a myocardial infarction. The approach involves both genetic and pharmacological methods to assess the effectiveness of this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently experienced a myocardial infarction and are at risk of developing heart failure.
Not a fit: Patients who have not had a heart attack or those with pre-existing heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve heart recovery and reduce the incidence of heart failure after heart attacks.
How similar studies have performed: While targeting ectonucleotidases is a relatively novel approach, previous research has shown promise in similar strategies for improving cardiac repair after injury.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEB, ARJUN — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: DEB, ARJUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.